Skip to main content

Table 2 Primary outcomes after 30 days and 60 days

From: Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak

 

ICS group (n = 51)

NICS group (n = 53)

p value

Symptoms after 60 days

Recovery

31 (60.8%)

36 (67.9%)

0.447

Improved

18 (35.3%)

14 (26.4%)

0.327

Not improved

2 (3.9%)

3 (5.7%)

1.000

CET

Baseline, median (IQR)

12.0 (9.0, 16.0)

10.0 (9.0, 13.0)

0.142

Day 30, median (IQR)

7.0 (6.0, 10.0) a

6.0 (5.5, 7.5) a

0.101

Day 60, median (IQR)

5.0 (5.0, 6.0) a

5.0 (5.0, 6.0) a

0.578

Day 30 change from baseline, median (IQR)

−5.0 (− 7.0, − 2.0)

−3.0 (− 5.0, − 2.0)

0.178

Day 60 change from baseline, median (IQR)

−7.0 (− 10.0, − 3.0)

−5.0 (− 7.0, − 3.0)

0.094

mMRC dyspnea score

Baseline, median (IQR)

1.0 (0.0, 2.0)

0.0 (0.0, 1.0)

0.167

Day 30, median (IQR)

0.0 (0.0, 1.0) a

0.0 (0.0, 1.0) a

0.511

Day 60, median (IQR)

0.0 (0.0, 0.0) a

0.0 (0.0, 0.0) a

0.361

Day 30 change from baseline, median (IQR)

0.0 (− 1.0, 0.0)

0.0 (− 1.0, 0.0)

0.200

Day 60 change from baseline, median (IQR)

0.0 (− 1.0, 0.0)

0.0 (− 1.0, 0.0)

0.218

  1. Symptom conditions at day 60 are presented as frequency (percentage). Values of CET, mMRC score, and change values are presented as median (IQR). CET: Cough evaluation test; IQR: interquartile range; mMRC: modified British Medical Research Council dyspnea scale; ICS: inhaled corticosteroid; NICS: non-inhaled corticosteroid. P value: ICS group versus NICS group. Compare to baseline: ap < 0.001